Jonathan W. Lee

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline <i>BRCA/PALB2</i> Mutation

Eileen M. O’Reilly, Jonathan W. Lee, Mark M. Zalupski et al. · Journal of Clinical Oncology · 2020 · 398 citations · Full text

Medicine, Molecular Medicine, Oncology +13

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms

Maeve A. Lowery, Winston Wong, Emmet Jordan et al. · JNCI Journal of the National Cancer Institute · 2018 · 224 citations · Full text

Medicine, Genetics, Oncology +17

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma

Maeve A. Lowery, David P. Kelsen, Marinela Capanu et al. · European Journal of Cancer · 2017 · 151 citations · Full text

Medicine, Oncology, Chemotherapy +8

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline <i>BRCA</i> mutation carriers and wild‐type <i>BRCA</i> pancreatic ductal adenocarcinoma

Eileen M. O’Reilly, Jonathan W. Lee, Maeve A. Lowery et al. · Cancer · 2018 · 103 citations

Medicine, Oncology, Pharmacology +12

Functional elements of the steroid hormone-responsive promoter of mouse mammary tumor virus

M G Toohey, Jonathan W. Lee, Mengqian Huang et al. · Journal of Virology · 1990 · 70 citations · Full text

Life Sciences, Genetics, Molecular Biology +17